Vascular safety of erenumab for migraine prevention

David Kudrow, MD, Julio Pascual, MD, PhD, Paul K. Winner, DO, David W. Dodick, MD, Stewart J. Tepper, MD, Uwe Reuter, MD, Frank Hong, MD, PhD, Jan Klatt, MD, Feng Zhang, MS, Sunfa Cheng, MD, Hernan Picard, MD, PhD, Osa Eisele, MD, MPH, Julie Wang, DPM, Jonathan N. Latham, PharmD, and Daniel D. Mikol, MD, PhD

Neurology® 2020;94:e497-e510. doi:10.1212/WNL.0000000000008743

Correspondence
Dr. Kudrow
dbkudrow@earthlink.net

Abstract

Objective
To examine the cardiovascular, cerebrovascular, and peripheral vascular safety of erenumab across migraine prevention studies.

Methods
Vascular adverse events (AEs) and blood pressure data were integrated across 4 double-blind, placebo-controlled studies of erenumab and their open-label extensions in patients with chronic or episodic migraine. Subgroup analyses were conducted by acute migraine-specific medication use and number of vascular risk factors at baseline. Standardized search terms were used to identify vascular AEs (cardiovascular, cerebrovascular, or peripheral). An independent committee adjudicated whether targeted events were vascular in origin.

Results
In placebo-controlled studies, 2,443 patients received placebo (n = 1,043), erenumab 70 mg (n = 893), or erenumab 140 mg (n = 507) subcutaneously once monthly. Regardless of acute migraine-specific medication use or vascular risk factors at baseline, AE incidence was similar across the placebo and erenumab treatment groups. Hypertension AEs were reported for 0.9% (placebo), 0.8% (erenumab 70 mg), and 0.2% (erenumab 140 mg) of patients. Vascular AEs, which were similar across double-blind and open-label treatment, generally were confounded, with plausible alternative etiologies. In 18 patients with events reviewed by the independent committee, 4 events were positively adjudicated as cardiovascular in origin: 2 deaths and 2 vascular events. All 4 positively adjudicated cardiovascular events occurred during open-label erenumab treatment.

Conclusion
Selective blockade of the canonical calcitonin gene-related peptide receptor with erenumab for migraine prevention had a vascular safety profile comparable to that of placebo over 12 weeks, with no increased emergence of events over time. Further study of long-term safety of erenumab in patients with migraine is needed.

Clinicaltrials.gov identifiers
NCT02066415, NCT02456740, NCT01952574, NCT02483585, NCT02174861, and NCT01723514.

Classification of evidence
This analysis provides Class II evidence that for patients with migraine, erenumab does not increase the risk of vascular AEs.
Glossary

AE = adverse event;  ARISE = Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) Compared to Placebo in Migraine Prevention;  BP = blood pressure;  CGRP = calcitonin gene-related peptide;  DBP = diastolic blood pressure;  SBP = systolic blood pressure;  MedDRA = Medical Dictionary for Regulatory Activities;  NSAID = nonsteroidal anti-inflammatory drug;  STRIVE = Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Migraine Prevention.

Migraine affects over 1 billion people worldwide and 15%–20% of Americans. More than 25% of adults with migraine are candidates for preventive therapy, but fewer than 30% of candidates receive it. Over 80% of patients with chronic migraine discontinue oral preventive therapy within the first year. There is an unmet need for an effective, well-tolerated therapy to prevent migraine.

Calcitonin gene-related peptide (CGRP) plays a key role in migraine pathophysiology. Monoclonal antibodies have recently been developed that bind to either CGRP or the canonical CGRP receptor to prevent migraine. Because CGRP can mediate vasodilation, inhibition of the CGRP pathway could theoretically attenuate compensatory vasodilation during ischemic conditions, but the relative importance of the CGRP receptor pathway compared with other vasodilatory pathways during ischemia (e.g., myocardial) has not been established. In addition, patients with migraine have an increased risk of vascular events, including stroke and myocardial ischemia, and acute migraine-specific medications such as triptans and ergotamine have known vasoconstrictive effects. Thus, it is important to examine vascular safety, particularly over the longer term, in patients treated with therapies that block the effects of CGRP.

Erenumab (in the United States, erenumab-aooe) is a fully human monoclonal antibody that specifically targets and blocks the canonical CGRP receptor to prevent migraine. Administered subcutaneously once monthly, erenumab has been shown to be effective for migraine prevention. This pooled analysis of vascular safety in clinical studies of erenumab for migraine prevention included vascular (cardiovascular, cerebrovascular, or peripheral) adverse events (AEs) that were reported by investigators, events that were adjudicated across all studies by an independent committee of clinical experts, and a pooled analysis of blood pressure (BP) measurements. This report also includes results of a 24-hour ambulatory BP monitoring study that assessed the potential cardiovascular effects of erenumab in healthy controls.

Methods

The primary research questions for this pooled analysis were to examine if the rates of vascular (cardiovascular or cerebrovascular) AEs were higher in the erenumab group vs the placebo group of controlled clinical studies, both overall and in subgroups of patients at a higher risk of vascular AEs, as well as the effect of erenumab treatment on BP. This analysis provides Class II evidence that for patients with migraine, erenumab does not increase the risk of vascular AEs.

Design

Information about AEs was collected as reported by the patient, either spontaneously or in response to the investigator’s nondirected questioning, per standard procedures in clinical trials. Regulatory authorities in the regions where the trials were conducted reviewed study protocols, including AE data collection methods, before implementation. Reported AEs and BP results were integrated for 12 weeks of double-blind treatment across 4 placebo-controlled migraine prevention studies of erenumab administered subcutaneously once monthly. For long-term safety, AE data were integrated for any exposure to erenumab in these 4 studies and their open-label extensions.

The pivotal studies testing the doses of erenumab that are approved for migraine prevention (70 mg and 140 mg once monthly) were NCT02066415 (n = 667), which enrolled patients with chronic migraine, and NCT02456740 (Study to Evaluate the Efficacy and Safety of Erenumab [AMG 334] in Migraine Prevention [STRIVE]; n = 955), which enrolled patients with episodic migraine. The supportive studies NCT01952574 (n = 483) and NCT02483585 (Study to Evaluate the Efficacy and Safety of Erenumab [AMG 334] Compared to Placebo in Migraine Prevention [ARISE]; n = 577) also enrolled patients with episodic migraine, but in the placebo-controlled periods of these studies, 70 mg was the highest dose tested. Safety data for erenumab doses less than 70 mg, which were investigated in the placebo-controlled period of supportive study NCT01952574 but are not approved for migraine prevention, were excluded from this integrated safety analysis. All but 1 of the studies had a 12-week placebo-controlled period; the episodic migraine STRIVE study had a 24-week placebo-controlled period. Patients assigned to an erenumab arm received the same dose (70 or 140 mg) throughout double-blind treatment.

Patients completing the double-blind, placebo-controlled periods were continued in an active dose-blinded treatment period (STRIVE study) or open-label erenumab treatment (all other studies). For the episodic migraine studies, following completion of the double-blind placebo-controlled period, the active treatment or open-label treatment period was part of the main study protocol. In NCT01952574, open-label erenumab is being maintained for up to 256 weeks (5 years). Patients who completed the chronic migraine study could enter a separate open-label extension study (NCT02174861).
During the active treatment or open-label periods, patients received only 70 mg (ARISE study), or 70 mg or 140 mg (other studies).

Ambulatory BP was assessed in a phase 1 study (NCT01723514) that enrolled 32 healthy controls and 16 patients with migraine who received erenumab (70 or 140 mg) or placebo subcutaneously once monthly for 12 weeks.22

**Standard protocol approvals, registrations, and patient consents**

An institutional review board or independent ethics committee approved each study in this analysis. The studies included in this analysis were registered at clinicaltrials.gov: NCT02066415, NCT02456740, NCT01952574, NCT02483585, NCT02174861, and NCT01723514. Patients provided written informed consent to participate in each study.

**Eligibility criteria**

Each of the migraine prevention studies had an initial screening period (up to 3 weeks), followed by a 4-week, prospective baseline period to confirm study eligibility before the patient was enrolled and randomized. Key inclusion criteria at screening were age 18 years or older (up to 60 or 65 years) and a history of migraine with or without aura for at least 12 months. The chronic migraine study included patients with at least 15 headache days per month during the baseline period, of which at least 8 were migraine days. The episodic migraine studies included patients with fewer than 15 headache days per month during the baseline period, of which at least 4 were migraine days.

In the episodic migraine studies, use of medications for acute headache before screening was restricted as follows: acute migraine-specific medications (tripタン or ergot) were limited to fewer than 10 days per month, analgesics or nonsteroidal anti-inflammatory drugs (NSAIDs) to fewer than 15 days per month, and opioids or butalbital-containing medications to fewer than 4 days per month. In the chronic migraine study, there was no restriction for prior use of acute migraine-specific medications, analgesics, or NSAIDs; however, in the prior 3 months, patients could not have used opioids on more than 12 days or butalbital on more than 6 days. In each migraine prevention study, after randomization, patients could use acute migraine-specific medications, analgesics, or NSAIDs as needed to treat acute migraine.

Patients were excluded from the migraine prevention studies if they had myocardial infarction, stroke, TIA, unstable angina, or coronary artery bypass surgery, or another revascularization procedure within 12 months prior to screening. Medically stable patients who had any of these listed conditions more than 12 months prior to screening could participate in the studies. Patients were excluded from studies NCT02066415 and NCT01952574 if they had poorly controlled hypertension (systolic BP [SBP] above 150–160 mm Hg or diastolic BP [DBP] above 90–100 mm Hg), and patients with any unstable medical condition were excluded from each study. Healthy controls in the ambulatory BP study had no history of hypertension, hypotension, or vascular disease.

**Safety assessments**

AEs that were new or worsened after the first dose of study treatment were recorded through 12 weeks after the last dose in studies with doses up to 70 mg (the ARISE study and study NCT01952574 before protocol amendment to include higher doses), and 16 weeks after the last dose in studies with doses up to 140 mg. For each AE, the Medical Dictionary for Regulatory Activities (MedDRA) was used to determine the preferred term and system organ class. AE severity was graded with Common Terminology Criteria for Adverse Events (CTCAE) criteria, version 4.03. A serious AE was defined as an AE that met at least 1 of the following criteria: fatal, life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, congenital anomaly/birth defect, or another medically important serious event.

Because of the acknowledged interest in the safety of this new class of medication, an independent committee was established to review potential vascular events. The adjudicators, who were clinical experts in cardiovascular and cerebrovascular disease, adjudicated each potential event based on prespecified definitions. Events that were referred to the adjudicators included the following: death, acute myocardial infarction or hospitalization for unstable angina event, non-fatal stroke or TIA, coronary revascularization procedure, hospitalization for hypertension, hospitalization for peripheral artery disease event, or revascularization procedure for peripheral artery disease. Adjudicators were blinded to treatment assignment throughout the adjudication process.

In each study, resting BP was measured at monthly study visits, before each administration of study treatment. The phase 1 study also monitored BP continuously for 24 hours, starting at 9:00 AM, on day –2 (i.e., 2 days before the first dose of study treatment) and on days 8, 36, and 64 (i.e., 7 days after each dose of study treatment).

**Statistical analysis**

Analyses of AEs were conducted for 2 pools of safety data. The “12-week placebo-controlled” pool was the integrated safety dataset from 12 weeks of double-blind treatment (or in the STRIVE study, the first 12 weeks of double-blind treatment). The “any erenumab exposure” pool included AEs that occurred during exposure to either double-blind or open-label erenumab treatment through the data cutoff for the 5-year open-label extension study (NCT01952574) or completion of the study (all other studies). Integrated analyses of AEs for the 12-week placebo-controlled pool were conducted by assigned treatment (placebo, erenumab 70 mg, or erenumab 140 mg). Integrated analyses for any erenumab exposure were
summarized by actual treatment received (erenumab 70 mg or erenumab 140 mg) when the AEs occurred. A single patient in the any erenumab exposure pool could have received both erenumab 70 mg and 140 mg because of the second randomization for the active treatment phase in the STRIVE study, or because of study protocol amendments in NCT02174861 and NCT01952574 that increased the open-label dose of erenumab from 70 mg to 140 mg for all patients. If a patient experienced the same AE when he or she received each dose of erenumab, then this AE was counted for both 70 mg and 140 mg. Exposure-adjusted incidence rates of AEs for any erenumab exposure pool were calculated by adjusting for the length of exposure to erenumab.

For the AE analyses in the 12-week placebo-controlled pool, 1 subgroup analysis examined the incidences of AEs separately by use or nonuse at baseline of acute migraine-specific medications (triptans or ergot). Another subgroup analysis examined the incidences of AEs separately by the number of vascular risk factors at baseline (none, 1, or ≥2) using 7 categories for vascular risk factors (table 1). Each subgroup analysis included incidences of any AE, any AE by severity, any serious AE, any AE leading to discontinuation of study treatment, and death.

To analyze vascular AEs, standardized MedDRA queries with narrow search terms were used to determine the overall incidences in each treatment group of the 12-week placebo-control pool in the following categories: ischemic CNS vascular conditions, ischemic heart disease, peripheral arterial disease, or hypertension. The same queries were used to analyze vascular AEs for any erenumab exposure. The results of each search were summarized descriptively. Positively adjudicated vascular events were listed.

The integrated data analysis of the 12-week double-blind pool also summarized resting SBP and DBP at monthly study visits. To evaluate BP in a manner that was clinically relevant, the proportion of patients with an increase from baseline of ≥10 mm Hg in DBP or ≥20 mm Hg in SBP was evaluated at the monthly visits. For the phase 1 study of ambulatory BP, hourly SBP and DBP were summarized for each treatment group.

Data availability
Qualified researchers may request data from Amgen clinical studies. Complete details are available at amgen.com/datasharing.

Results

Patient disposition
During 12 weeks of double-blind treatment across the 4 migraine prevention studies, 2,443 patients with migraine received placebo (n = 1,043), erenumab 70 mg (n = 893), or erenumab 140 mg (n = 507). Most of these patients (94% erenumab, 92% placebo) completed 12 weeks of double-blind treatment. In NCT01952574, an additional 213 patients who received lower doses of erenumab 7 mg (n = 108) or 21 mg (n = 105) were not included in the pooled safety analysis for 12 weeks of double-blind treatment but could be analyzed for AEs during any exposure to erenumab if they switched to 70 mg for the open-label phase.

For the analysis of AEs during any exposure to erenumab, 2,499 patients received at least 1 dose of erenumab 70 mg (n = 2,128) or at least 1 dose of erenumab 140 mg (n = 1,223). A single patient in any study except ARISE could have received both erenumab 70 mg and 140 mg. Thus, considering all erenumab exposure during double-blind or open-label treatment, 852 patients received both doses of erenumab, 1,276 received only 70 mg, and 371 received only 140 mg. The total exposure to either dose of erenumab was 2,639 patient-years.

Patient characteristics
Baseline patient characteristics, use of acute migraine-specific medications, and vascular risk factors were balanced across the treatment groups (table 2). Upon entry into the respective study, mean patient age in each treatment group was 41.3–41.8 years, and 83.3%–85.0% of patients were female. Mean disease duration was approximately 21 years in each treatment group, and the mean number of monthly migraine days in each treatment group was 10.3–11.9. At baseline, acute migraine-specific medications were used by 64.1%–66.9% of patients in each treatment group. Almost all of the acute migraine-specific medications used were triptans (<1% were ergot-based). Medications for management of hypertension were used at baseline by 3.7%–6.5% of patients in each treatment group.

Table 1 Determination of baseline vascular risk factors from reported data

| Category                      | Description                                                                 |
|-------------------------------|-----------------------------------------------------------------------------|
| Diabetes mellitus             | History of diabetes mellitus                                                |
| Hypertension                  | Medical history of hypertension or high blood pressure at screening (≥2 occasions with systolic >140 mm Hg or diastolic >90 mm Hg) |
| Obesity                       | Body mass index >30 kg/m²                                                   |
| Dyslipidemia                  | Total cholesterol >200 mg/dL or low-density lipoprotein cholesterol >130 mg/dL or high-density lipoprotein cholesterol <40 mg/dL or triglycerides >150 mg/dL or medical history of dyslipidemia |
| Cigarette use                 | History of smoking                                                         |
| Coronary artery disease       | Ischemic heart disease (as reported in case report forms for dedicated vascular medical history or for general medical history) |
| Cerebrovascular or peripheral artery disease | Cerebrovascular disease or peripheral artery disease (as reported in case report forms for dedicated vascular medical history or for general medical history) or medical history of peripheral vasoconstriction, necrosis, or vascular insufficiency |
Table 2 Patient demographic and clinical characteristics at baseline in 4 migraine prevention studies

| Baseline characteristic | Placebo QM (n = 1,043) | Erenumab 70 mg QM (n = 893) | Erenumab 140 mg QM (n = 507) |
|-------------------------|------------------------|----------------------------|-----------------------------|
| Age, y                  | 41.8 ± 11.1            | 41.7 ± 11.2                | 41.3 ± 11.2                 |
| Female                  | 869 (83.3)             | 755 (84.5)                 | 431 (85.0)                  |
| White                   | 934 (89.5)             | 813 (91.0)                 | 475 (93.7)                  |
| North America           | 544 (52.2)             | 471 (52.7)                 | 248 (48.9)                  |
| Body mass index, kg/m²  | 26.8 ± 5.8             | 26.9 ± 5.8                 | 26.7 ± 6.0                  |
| Disease duration, y     | 20.7 ± 12.2            | 20.8 ± 12.4                | 20.5 ± 12.2                 |
| History of migraine with aura | 481 (46.1)       | 429 (48.0)                 | 231 (45.6)                  |
| History of migraine without aura | 925 (88.7)          | 788 (88.2)                 | 450 (88.8)                  |
| Monthly migraine days   | 11.1 ± 5.5             | 10.3 ± 5.0                 | 11.9 ± 5.8                  |
| Acute headache medication use |                      |                            |                             |
| Any                     | 1,024 (98.2)           | 872 (97.6)                 | 498 (98.2)                  |
| Migraine-specific⁷       | 690 (66.2)             | 572 (64.1)                 | 339 (66.9)                  |
| Non-migraine-specific   | 822 (78.8)             | 705 (78.9)                 | 416 (82.1)                  |
| Any hypertension medication use | 68 (6.5)           | 33 (3.7)                   | 22 (4.3)                    |
| History of vascular disorders | 77 (7.4)            | 59 (6.6)                   | 50 (9.9)                    |
| No. of vascular risk factors |                      |                            |                             |
| 0                       | 310 (29.7)             | 233 (26.1)                 | 148 (29.2)                  |
| 1                       | 423 (40.6)             | 377 (42.2)                 | 199 (39.3)                  |
| ≥2                      | 310 (29.7)             | 283 (31.7)                 | 160 (31.6)                  |
| Vascular risk factors   |                        |                            |                             |
| High cholesterol level⁸ | 489 (46.9)             | 438 (49.0)                 | 241 (47.5)                  |
| Obesity²                | 253 (24.3)             | 230 (25.8)                 | 133 (26.2)                  |
| High lipid level⁹       | 250 (24.0)             | 227 (25.4)                 | 122 (24.1)                  |
| History of diabetes mellitus | 21 (2.0)            | 17 (1.9)                   | 6 (1.2)                     |
| History of dyslipidemia | 93 (8.9)               | 69 (7.7)                   | 31 (6.1)                    |
| History of hypertension | 93 (8.9)               | 51 (5.7)                   | 34 (6.7)                    |
| High blood pressure at screening³ | 73 (7.0)         | 58 (6.5)                   | 34 (6.7)                    |
| History of cigarette use |                        |                            |                             |
| Current                 | 64 (6.1)               | 67 (7.5)                   | 41 (8.1)                    |
| Former                  | 114 (10.9)             | 93 (10.4)                  | 51 (10.1)                   |
| Never                   | 430 (41.2)             | 437 (48.9)                 | 227 (44.8)                  |
| Unknown                 | 435 (41.7)             | 296 (33.1)                 | 188 (37.1)                  |

Abbreviation: QM = once monthly.
Data are presented as mean ± SD or number (%) of patients.
* Includes triptan-based or ergot-based medications (<1% received ergot-based medications).
⁷ High cholesterol level is defined as one of the following: total cholesterol >200 mg/dL, low-density lipoprotein cholesterol >130 mg/dL, or high-density lipoprotein cholesterol <40 mg/dL.
² Obesity is defined as a body mass index >30 kg/m².
⁹ High lipid level is defined as triglycerides >150 mg/dL.
³ High blood pressure at screening is defined as systolic blood pressure >140 mm Hg or diastolic blood pressure >90 mm Hg measured on at least 2 occasions.
In each treatment group, 6.6%–9.9% of patients had a history of a vascular disorder, most commonly hypertension (3.4%–5.1%). More than 70% of patients in each treatment group had at least 1 vascular risk factor at baseline (table 2). The most common vascular risk factor at baseline was dyslipidemia (based on high cholesterol, high lipids, or history of dyslipidemia). One in 4 patients was obese.

### Vascular adverse events in targeted searches

In the targeted searches for vascular AEs during 12 weeks of double-blind treatment, investigators reported AEs of hypertension or diastolic hypertension for 9 (0.9%) patients receiving placebo, 7 (0.8%) receiving erenumab 70 mg, and 1 (0.2%) receiving erenumab 140 mg (table 3). An AE of cerebral venous thrombosis was reported for 1 (0.2%) patient in the erenumab 140 mg group; review of the event did not suggest a causal association for erenumab. This female patient had multiple risk factors for venous thrombosis: age ≥40 years, body mass index >30 kg/m², a prior history of deep vein thrombosis and pulmonary embolism, recurrent heparin-induced thrombocytopenia, and a recent infection (sepsis, pyelonephritis, and kidney infection about 7 weeks before the event). No other ischemic vascular event was reported in any treatment group in the pooled 12-week placebo-controlled analysis.

In the targeted searches for vascular AEs during any erenumab exposure (either double-blind or open-label), the exposure-adjusted patient incidence rate for an AE of hypertension was 2.5 per 100 patient-years for erenumab 70 mg and 1.7 per 100 patient-years for erenumab 140 mg (table 3). The exposure-adjusted patient incidence rate for an AE of cerebral venous thrombosis was 0.2 per 100 patient-years for 140 mg, including the AE described above for the double-blind period and another AE during open-label erenumab treatment. The latter AE occurred in a 38-year-old man who experienced subdural hematoma, cerebral venous thrombosis, and facial bone fractures as a result of closed head injury sustained during a fall while hiking. He was found unconscious and under the influence of Ecstasy (3,4-methylenedioxy-methamphetamine). Two patients had an AE of myocardial ischemia (<0.1 per 100 patient-years for 70 mg), both of which occurred during open-label erenumab treatment. One of these patients had demand ischemia that was a positively adjudicated vascular event (see description in the next section). The other patient had exercise-induced ischemia and had taken sumatriptan 4 hours before the exercise test. This patient received a total of 2 doses of erenumab 70 mg, with the second dose 36 days before the event. The dose of sumatriptan on the day of the event was 50 mg, and the patient’s previous dose of sumatriptan was administered 68 days before the event. Other AEs in the searches for vascular events occurred in only 1 patient each. Review of the individual events did not suggest a causal association for erenumab.

### Adjudicated vascular events

Eighteen patients had AEs that fulfilled criteria for adjudication. The blinded, independent, clinical experts adjudicated the events as cardiovascular in origin for 4 patients. All occurred during open-label erenumab treatment. For each adjudicated event, investigators considered the respective AEs as not related to erenumab treatment; adjudicators did not assess the relationship of positively adjudicated events to treatment. Details on these 4 events are given below.

A 55-year-old woman in the ARISE study had AEs of multifocal pneumococcal bacteremia, life-threatening acute respiratory distress syndrome, atrial fibrillation, myocardial (demand) ischemia, and elevated troponin levels on day 135, during open-label treatment with erenumab 70 mg.

A 54-year-old man in study NCT01952574 with a history of hypertensive cardiovascular disease died of arteriosclerosis and hypertensive heart disease on day 650 of exposure during open-label treatment with erenumab 70 mg. On autopsy, there was evidence of severe coronary atherosclerosis with presence of alcohol and stimulants (phenylpropanolamine and norpseudoephedrine). This case was reported previously.

A 44-year-old man in the STRIVE study with body mass index of 30 kg/m², high triglycerides, a history of abnormal ECG findings (first-degree atrioventricular block, intraventricular conduction defect, and anomalies of repolarization), and mild mitral prolapse died after 12 months of exposure to erenumab during open-label treatment with 140 mg. He was asymptomatic for the duration of the study, including during physical exertion. Postmortem genetic assessment revealed a genetic form of arrhythmogenic right ventricular cardiomyopathy/dysplasia, which predisposes to sudden cardiac death. Consistent with this diagnosis, postmortem findings included hyperplastic sclerosis of coronary arteries, fat infiltration of the right heart chamber musculature, hypertrophy of the left cardiac musculature, and dilation of both cardiac chambers. The direct cause of death was attributed to heart failure.

A 64-year-old man in study NCT02174861 with a history of hypertension and migraine with aura had monocular visual blurring lasting 2 minutes on day 209 of exposure during open-label treatment with erenumab 140 mg (10 weeks after last dose). The event was reported as an AE of TIA.

### AEs by use of acute migraine-specific medications

Patients who used acute migraine-specific medications at baseline had similar incidences of AEs and serious AEs across the placebo and erenumab treatment groups (table 4). Overall, patients using acute migraine-specific medications had a slightly higher incidence of serious AEs compared with nonusers of acute migraine-specific medications. There was no evidence of an increased incidence of vascular AEs or serious vascular AEs among patients using acute migraine-specific medications.

### AEs by number of vascular risk factors at baseline

Regardless of the number of vascular risk factors at baseline, incidences of AEs were similar across the placebo and
erenumab treatment groups (table 5). In the subgroup of patients with at least 2 vascular risk factors at baseline, there were slightly higher incidences of AEs or serious AEs compared with the subgroups of patients with no risk factor or 1 risk factor at baseline, but incidences were balanced across the placebo and erenumab groups. There was no evidence of an increased incidence of vascular AEs or serious vascular AEs among patients with vascular risk factors at baseline.

### Table 3 Treatment-emergent vascular adverse events in migraine prevention studies

| Category                        | Preferred term                        | During 12 weeks of double-blind treatment | During any exposure to erenumab |
|---------------------------------|---------------------------------------|------------------------------------------|---------------------------------|
|                                 |                                       | Placebo QM (n = 1,043)                   | Erenumab 70 mg QM (n = 893)     | Erenumab 140 mg QM (n = 507)   | 70 mg QM (n = 2,128)         | 140 mg QM (n = 1,223)         |
|                                 |                                       | Erenumab 70 mg QM (n = 893)             |                                 |                                 |                                 |                                 |
|                                 |                                       | Erenumab 140 mg QM (n = 507)            |                                 |                                 |                                 |                                 |
|                                 |                                       |                                           |                                 |                                 |                                 |                                 |
| Ischemic CNS vascular conditions| Ischemic CNS vascular conditions      | 0 (0.0)                                  | 0 (0.0)                         | 1 (0.2)                         | 0 (0.0) 2,062.2 [0.0]         | 4 (0.3) 2,015.1 [0.4]          |
|                                 | Cerebral venous thrombosis            | 0 (0.0)                                  | 0 (0.0)                         | 1 (0.2)                         | 0 (0.0) 2,062.2 [0.0]         | 2 (0.2) 2,016.2 [0.2]          |
|                                 | Cerebrovascular disorder              | 0 (0.0)                                  | 0 (0.0)                         | 0 (0.0)                         | 0 (0.0) 2,062.2 [0.0]         | 1 (<0.1) 2,015.4 [0.1]         |
|                                 | TIAa                                   | 0 (0.0)                                  | 0 (0.0)                         | 0 (0.0)                         | 0 (0.0) 2,062.2 [0.0]         | 1 (<0.1) 2,016.3 [0.1]         |
| Ischemic heart disease          | Ischemic heart disease                | 0 (0.0)                                  | 0 (0.0)                         | 0 (0.0)                         | 5 (0.2) 2,066.2 [0.2]         | 0 (0.0) 1,016.4 [0.0]          |
|                                 | Myocardial ischemiaa                  | 0 (0.0)                                  | 0 (0.0)                         | 0 (0.0)                         | 2 (<0.1) 2,067.5 [0.1]        | 0 (0.0) 1,016.4 [0.0]          |
|                                 | Angina pectoris                        | 0 (0.0)                                  | 0 (0.0)                         | 0 (0.0)                         | 1 (<0.1) 2,067.7 [0.1]        | 0 (0.0) 1,016.4 [0.0]          |
|                                 | Arteriosclerosis coronary artery       | 0 (0.0)                                  | 0 (0.0)                         | 0 (0.0)                         | 1 (<0.1) 2,067.8 [0.1]        | 0 (0.0) 1,016.4 [0.0]          |
|                                 | Blood CPK-MB increased                 | 0 (0.0)                                  | 0 (0.0)                         | 0 (0.0)                         | 1 (<0.1) 2,067.9 [0.1]        | 0 (0.0) 1,016.4 [0.0]          |
|                                 | Peripheral arterial disease            | 0 (0.0)                                  | 0 (0.0)                         | 0 (0.0)                         | 1 (<0.1) 2,067.9 [0.1]        | 1 (<0.1) 1,015.7 [0.1]         |
|                                 | Raynaud phenomenon                    | 0 (0.0)                                  | 0 (0.0)                         | 0 (0.0)                         | 1 (<0.1) 2,067.9 [0.1]        | 1 (<0.1) 1,015.7 [0.1]         |
|                                 | Hypertension                          | 9 (0.9)                                  | 7 (0.8)                         | 1 (0.2)                         | 50 (2.3) 2,034.8 [2.5]        | 17 (1.4) 1,007.1 [1.7]         |
|                                 | Hypertension                          | 9 (0.9)                                  | 7 (0.8)                         | 0 (0.0)                         | 41 (1.9) 2,039.4 [2.0]        | 15 (1.2) 1,008.9 [1.5]         |
|                                 | Diastolic hypertension                | 0 (0.0)                                  | 0 (0.0)                         | 1 (0.2)                         | 0 (0.0) 2,062.2 [0.0]         | 1 (<0.1) 1,015.1 [0.1]         |
|                                 | Blood pressure increased               | 0 (0.0)                                  | 0 (0.0)                         | 0 (0.0)                         | 7 (0.3) 2,063.8 [0.3]         | 1 (<0.1) 1,015.9 [0.1]         |
|                                 | Blood pressure diastolic increased    | 0 (0.0)                                  | 0 (0.0)                         | 0 (0.0)                         | 1 (<0.1) 2,068.1 [0.1]        | 0 (0.0) 1,016.4 [0.0]          |
|                                 | Hypertensive heart diseasa             | 0 (0.0)                                  | 0 (0.0)                         | 0 (0.0)                         | 1 (<0.1) 2,068.2 [0.1]        | 0 (0.0) 1,016.4 [0.0]          |

Abbreviations: CPK-MB = creatine phosphokinase–muscle/brain; QM = once monthly.

Data for double-blind treatment are presented as number (%) of patients who received at least 1 dose of 70 mg or 1 dose of 140 mg (the same patient could have received both doses). Data for any exposure to erenumab are presented as number (%) of patients/total time at risk in years [exposure-adjusted incidence rate per 100 patient-years], where total time at risk was the time from the patient’s first dose of erenumab 70 mg or 140 mg to onset of the first event or, if no event occurred, to the earliest of patient’s end of safety follow-up (12 or 16 weeks after last dose of 70 mg or 140 mg, respectively), end of study, or data cutoff date. Each erenumab dose group includes adverse events while the patient received that dose. Multiple events of the same preferred term are only counted once per patient.

* Four patients had a positively adjudicated vascular event, including 1 patient each with a vascular adverse event of TIA, myocardial ischemia, and hypertensive heart disease, plus 1 patient without a reported vascular adverse event.

### Blood pressure changes

In the integrated analysis of the 4 migraine prevention studies, resting BP readings were similar across the treatment groups and across the study visits (figure 1). Mean (SD) change in SBP from baseline to week 12 was −0.4 (9.6) mm Hg in the placebo group, −0.5 (10.0) mm Hg in the erenumab 70 mg group, and −1.0 (9.8) mm Hg in the erenumab 140 mg group. Mean (SD) change in DBP from baseline to week 12 was −0.6
(7.1) mm Hg in the placebo group, −0.3 (7.7) mm Hg in the erenumab 70 mg group, and −0.4 (7.2) mm Hg in the erenumab 140 mg group.

There were no clinically relevant differences across treatment groups for a SBP increase of ≥20 mm Hg or a DBP increase of ≥10 mm Hg from baseline at weeks 4, 8, and 12 (table 6).

In the 24-hour continuous BP monitoring study, SBP and DBP after 12 weeks of treatment in healthy controls were similar in the erenumab 70 mg group and the erenumab 140 mg group compared with the placebo group, and erenumab had no effect on the diurnal pattern of BP (figure 2). Similar results were observed for 24-hour continuous BP monitoring after the first and second monthly doses of placebo or erenumab in healthy controls, or after each dose of study treatment in patients with migraine (data not shown).

Discussion

During 12 weeks of double-blind treatment in 4 clinical studies of migraine prevention, the incidences of AEs were similar across the placebo, erenumab 70 mg, and erenumab 140 mg groups, with no evidence of dose dependency for safety. Review of both individual and aggregate AEs did not find evidence of an association between erenumab treatment and vascular events, including cardiovascular, cerebrovascular,
or peripheral vascular events. Vascular ischemic events occurred during open-label erenumab treatment and were confounded with plausible alternative etiologies.

Subgroup analyses were conducted to examine the overall safety of erenumab in patients with migraine who might be at higher risk of vascular events. Approximately two-thirds of the patients were using an acute migraine-specific medication at baseline. Triptans and ergot-based medications have vasoconstrictive effects that may contribute to a higher risk of cardiovascular or cerebrovascular AEs with these acute medications. Thus, triptans and ergot-based medications have relative contraindications for use in patients at high risk of vascular events, which includes more than 900,000 men and women with migraine in the United States. In this analysis, the incidences of AEs were similar between the erenumab and placebo groups, supporting that adding erenumab to an acute migraine-specific medication did not increase risk compared with adding placebo to an acute migraine-specific medication. Overall, users of acute migraine-specific medications had a slightly higher incidence of serious AEs compared with nonusers of acute migraine-specific medications.

Among patients with common vascular risk factors at baseline, the incidences of AEs were similar across the placebo and erenumab treatment groups. Regardless of treatment group, the incidences of AEs and serious AEs were slightly higher in the subgroup of patients with at least 2 vascular risk factors than in those with 0 or 1 risk factor.

Erenumab treatment for 12 weeks also had no relevant effect on BP compared with placebo, either for resting measurements at monthly study visits in patients with episodic or chronic migraine, or for continuous 24-hour ambulatory BP monitoring after 12 weeks of treatment. There were no clinically relevant differences in the number of patients with a ≥10 mm Hg increase in DBP or a ≥20 mm Hg increase in SBP, no difference between erenumab and placebo for mean SBP or DBP, and no imbalances in outliers for BP. This is consistent with the similar incidence of clinically reported AEs of hypertension between the placebo and erenumab treatment groups during the first 12 weeks of the placebo-controlled studies, and a similar incidence of hypertension AEs during long-term erenumab treatment. Collectively, these analyses supported the vascular safety profile for erenumab across different study periods, populations, and methodologies, providing a comprehensive examination of the safety of erenumab treatment for migraine prevention.

Supportive information for these findings was provided by ex vivo studies that showed no vasoactive effect of erenumab.

Figure 1 Blood pressure by visit in patients with migraine during 12 weeks of double-blind treatment in 4 migraine prevention studies

| Blood pressure (mmHg) | Placebo (n = 1,043) | Erenumab 70 mg QM (n = 893) | Erenumab 140 mg QM (n = 507) |
|-----------------------|---------------------|-----------------------------|-----------------------------|
| Systolic              | Maximum             | 3rd quartile                | Median                      | 1st quartile               |
| Diastolic             |                     |                             |                             |                           |
| Baseline              | n = 1,043           | 985                         | 860                         | 482                        |
| Week 4                | 1,022               | 871                         | 497                         |
| Week 8                | 1,043               | 893                         | 507                         |
| Week 12               | 1,043               | 893                         | 507                         |

QM = once monthly.
beyond its blockade of the vasodilatory effect of CGRP. In those studies, which measured arterial segments from brain and coronary vessels, exposure to erenumab alone did not affect vascular contractility. Because erenumab is selective for the canonical CGRP receptor, the absence of an effect of erenumab on vascular tone may not be generalizable to other agents that block CGRP from binding to other receptors in the calcitonin-like receptor family or to the CGRP ligand itself.

Recent clinical studies provide additional support for the vascular safety of erenumab. An exercise treadmill safety study in 88 patients with coronary artery disease and stable angina showed no aggravation of myocardial ischemia in the patients who received erenumab compared with those who received placebo. Erenumab did not decrease exercise duration as measured by the change from baseline in total exercise time compared to placebo (the primary endpoint of the study). That study enrolled patients with coronary artery disease and stable angina; the study population was older (median age ~65 years) and contained a higher proportion of men (78%) than this pooled analysis.

A drug–drug interaction study in 34 healthy controls found that concomitant administration of erenumab 140 mg with the acute migraine-specific medication sumatriptan had no clinically meaningful or additive effects on resting BP compared with sumatriptan alone. Because the healthy controls in the latter study received sumatriptan, those with elevated BP or heart rate, a prolonged QT interval, or a history of major vascular event or major cardiovascular intervention were excluded from the study.

Strengths of this safety analysis in approximately 2,500 patients with migraine were the size and characteristics of the patient population and the overall extent of exposure to erenumab. Patient demographics (mostly female and mean age of approximately 40 years) were representative of patients with migraine, supporting the generalizability of the results to other patients with chronic or episodic migraine. Safety results from the individual studies were also consistent across patients with either chronic or episodic migraine. The number of patients was complemented by duration of exposure. The total exposure to erenumab was 2,639 patient-years, and one of the episodic migraine studies includes open-label

| Table 6 | Percentage of patients by visit with increases from baseline in blood pressure during 12 weeks of double-blind treatment in 4 migraine prevention studies |
|---------|-------------------------------------------------------------------------------------------------------------------|
| Week 4  | No. of patients with SBP/DBP result | Placebo QM (n = 1,043) | Erenumab 70 mg QM (n = 893) | Erenumab 140 mg QM (n = 507) |
|         | SBP increase ≥20 mm Hg to SBP ≤140 mm Hg | 15 (1.5) | 14 (1.6) | 8 (1.6) |
|         | SBP increase ≥20 mm Hg to SBP >140 mm Hg | 9 (0.9) | 6 (0.7) | 3 (0.6) |
|         | DBP increase ≥10 mm Hg to DBP ≤90 mm Hg | 57 (5.6) | 61 (6.9) | 46 (9.2) |
|         | DBP increase ≥10 mm Hg to DBP >90 mm Hg | 10 (1.0) | 19 (2.2) | 2 (0.4) |
| Week 8  | No. of patients with SBP/DBP result | 997 | 871 | 497 |
|         | SBP increase ≥20 mm Hg to SBP ≤140 mm Hg | 12 (1.2) | 17 (2.0) | 7 (1.4) |
|         | SBP increase ≥20 mm Hg to SBP >140 mm Hg | 3 (0.3) | 6 (0.7) | 3 (0.6) |
|         | DBP increase ≥10 mm Hg to DBP ≤90 mm Hg | 58 (5.8) | 65 (7.5) | 47 (9.5) |
|         | DBP increase ≥10 mm Hg to DBP >90 mm Hg | 15 (1.5) | 12 (1.4) | 2 (0.4) |
| Week 12 | No. of patients with SBP/DBP result | 985 | 860 | 482 |
|         | SBP increase ≥20 mm Hg to SBP ≤140 mm Hg | 10 (1.0) | 24 (2.8) | 8 (1.7) |
|         | SBP increase ≥20 mm Hg to SBP >140 mm Hg | 8 (0.8) | 8 (0.9) | 4 (0.8) |
|         | DBP increase ≥10 mm Hg to DBP ≤90 mm Hg | 70 (7.1) | 67 (7.8) | 44 (9.1) |
|         | DBP increase ≥10 mm Hg to DBP >90 mm Hg | 12 (1.2) | 12 (1.4) | 7 (1.5) |

Abbreviations: DBP = diastolic blood pressure; QM = once monthly; SBP = systolic blood pressure. Data are presented as number (%) of patients, except as specified.
treatment for up to 5 years. As noted above, the exclusion of patients with major vascular events within 12 months before each study was a limitation of the analysis, but this is typical for most studies of migraine treatment or prevention. In addition, patients with symptomatic vascular disease for more than 12 months before screening were allowed to participate in the erenumab studies of migraine prevention. Hypertension was not an exclusion criterion in the ARISE or STRIVE studies, and patients could participate in the other studies if they did not have poorly controlled hypertension. Thus, patients who might be excluded from many migraine prevention studies were allowed to enroll in the erenumab studies.

This safety analysis used data from the controlled setting of clinical trials. Additional safety data from real-world analyses would be useful to confirm the vascular safety of erenumab with widespread use in a broader patient population. A placebo comparator group was not available for the longer-term safety data in this analysis. A limitation of any open-label study...
is contextualization of events that occur when there is no comparator group. Assessment and adjudication of potential vascular ischemic events by a panel of clinical experts confirmed only 4 events as being vascular in origin. Each occurred during open-label erenumab treatment, when the adjudicators were not blinded to the patient’s study treatment. While the independent adjudicators did not determine treatment-relatedness, the investigators did not consider any of these events to be related to treatment. BP also seems to have been unaffected by erenumab treatment. If cardiovascular and cerebrovascular AEs do not occur more often, it might still be speculated that their severity is increased with blockade of the CGRP receptor. In these clinical studies, investigators were not specifically asked to judge whether the study treatment influenced the severity of vascular AEs. Given the rarity of these events (only 4 events in the whole dataset were deemed cardiovascular in origin), only substantial long-term real-world safety data will help address this question. Standardized searches for AE terms of vascular events used narrow search terms to increase specificity of the analyses. Sensitivity analyses using broad search terms identified 2 additional events that were not specific to vascular injury during any exposure to erenumab: T-wave inversion on ECG (n = 1) and increase in blood creatine phosphokinase (n = 17). Review of the individual AEs of increased blood creatine phosphokinase indicated that these were isolated events with no association with cardiac injury (most of them related to intense physical activity).

In this integrated analysis, erenumab had a vascular safety profile comparable to that of placebo over 12 weeks, and the overall safety profiles for erenumab and placebo were similar regardless of whether patients also used an acute migraine-specific medication or had risk factors for vascular events. A vascular safety signal did not emerge with longer-term treatment with dose-blinded or open-label erenumab for up to 256 weeks. Results from ex vivo studies and other clinical studies provided support for the vascular safety of erenumab treatment. Further study of long-term vascular safety of erenumab in patients with migraine is needed.

**Study funding**

This study was funded by Amgen Inc. and Novartis.

**Disclosure**

D. Kudrow has participated in advisory boards for Amgen, Novartis, Alder, Eli Lilly, Biohaven, and Promius; and has received research support from Amgen-Novartis, Alder, Teva, Eli Lilly, Biohaven, Zosano, Allergan, Roche-Genentech, Dr. Reddy’s Laboratories, Novartis, and UCB. J. Pascual has received research support from Allergan and personal fees from Allergan, Stendhal, and Amgen-Novartis. P. Winner is an investigator in clinical trials sponsored by Teva, Amgen, Genentech, Novartis, Allergan, AstraZeneca, Biogen Idec, Ipsen, and Lilly; has participated in advisory boards for Teva, Amgen, Avanir, Novartis, Allergan, Supernus, and Lilly; and has been on speakers’ bureaus for Allergan, Amgen, Avanir, Lilly, Promius, Novartis, and Supernus. D. Dodick has received personal fees from Amgen, Association of Translational Medicine, University Health Network, Daniel Edelman Inc., Autonomic Technologies, Axsome, Aural Analytics, Allergan, Alder, Biohaven, Charlestown Laboratories, Dr. Reddy’s Laboratories/Promius, Electrocore LLC, Eli Lilly, eNeura, Neurolief, Novartis, Ipsen, Impel, Satsuma, Supernus, Sun Pharma (India), Theranica, Teva, Vedanta, WL Gore, Nocira, PSL Group Services, University of British Columbia, Zosano, ZP Opco, Foresite Capital, and Oppenheimer; has received CME fees or royalty payments from Healthlogix, Medicom Worldwide, Medlogix Communications, Mednet, Miller Medical, PeerView, WebMD Health/Medscape, Chameleon, Academy for Continued Healthcare Learning, Universal Meeting Management, Haymarket, Global Scientific Communications, Global Life Sciences, Global Access Meetings, UpToDate (Elsevier), Oxford University Press, Cambridge University Press, and Wolters Kluwer Health; has stock options for Aural analytics, Healint, Theranica, Second Opinion/Mobile Health, Epien, GBS/Nocira, Matterhorn/Ontologics, and King-Devick Technologies; has been a consultant without fee for Aural Analytics, Healint, Second Opinion/Mobile Health, and Epien; has a board of directors position for Epien, Matterhorn/Ontologics, and King-Devick Technologies; has a patent without a fee (Botulinum Toxin Dosage Regimen for Chronic Migraine Prophylaxis); has received professional society fees or reimbursement for travel from American Academy of Neurology, American Brain Foundation, American Headache Society, American Migraine Foundation, International Headache Society, and Canadian Headache Society; and has a use agreement through employer for Myndshift. S. Tepper has received research support (no personal compensation) from Alder, Allergan, Amgen, ATI, Dr. Reddy’s, ElectroCore, eNeura, Neurolief, Scion Neurostim, Teva, and Zosano; is a consultant for Acorda, Alder, Alexxa, Allergan, Alphasights, Amgen, ATI, Axsome Therapeutics, Biohaven, Charleston Labs, DeepBench, Dr. Reddy’s, ElectroCore, Eli Lilly, eNeura, GLG, Guidepoint Global, GSK, M3 Global Research, Magellan Rx Management, Medicxii, Navigant Consulting, Neurolief, Nordic BioTech, Novartis, Pfizer, Reckner Healthcare, Relevate, Satsuma, Scion Neurostim, Slingshot Insights, Sorrento, Sudler and Hennessy, Supernus, Teva, Theranica, Trinity Partners, XOC, and Zosano; holds stock options from ATI; receives royalties from Springer; and receives a salary from Dartmouth-Hitchcock Medical Center and the American Headache Society. U. Reuter has received personal fees from Amgen, Alder, Allergan, Autonomic Technologies, Eli Lilly, ElectroCore, Medscape, Novartis, StreaMedUp, and Teva. F. Hong is an employee and stockholder of Novartis. J. Klatt is an employee and stockholder of Amgen Inc. S. Cheng is an employee and stockholder of Amgen Inc. H. Picard is an employee and stockholder of Amgen Inc. O. Eisele is an employee and stockholder of Amgen Inc. J. Wang is an employee and stockholder of Amgen Inc. J. Latham received personal fees from Amgen Inc. for medical writing support. D. Mikol is an employee and stockholder of Amgen Inc. Go to Neurology.org/N for full disclosures.
Appendix Authors

| Name            | Location                              | Role          | Contribution                                                                 |
|-----------------|---------------------------------------|---------------|-----------------------------------------------------------------------------|
| David Kudrow, MD| California Medical Clinic for Headache, Santa Monica | Author        | Major role in the acquisition of data, interpreted the data, revised the manuscript for intellectual content |
| Julio Pascual, MD, PhD | Department of Neurology and IDIVAL, University Hospital Marqués de Valdecilla, Santander, Spain | Author        | Major role in the acquisition of data, interpreted the data, revised the manuscript for intellectual content |
| Paul K. Winner, DO | Premier Research Institute, Nova Southeastern University, West Palm Beach, FL | Author        | Major role in the acquisition of data, interpreted the data, revised the manuscript for intellectual content |
| David W. Dodick, MD | Department of Neurology, Mayo Clinic, Phoenix, AZ | Author        | Major role in the acquisition of data, interpreted the data, revised the manuscript for intellectual content |
| Stewart J. Tepper, MD, FAHS | Department of Neurology, Geisel School of Medicine at Dartmouth, Hanover, NH | Author        | Major role in the acquisition of data, interpreted the data, revised the manuscript for intellectual content |
| Uwe Reuter, MD | Department of Neurology, Charité Universitätsmedizin Berlin, Germany | Author        | Major role in the acquisition of data, interpreted the data, revised the manuscript for intellectual content |
| Frank Hong, MD, PhD | Novartis, East Hanover, NJ | Author        | Interpreted the data, revised the manuscript for intellectual content |
| Jan Klatt, MD | Novartis, Basel, Switzerland | Author        | Interpreted the data, revised the manuscript for intellectual content |
| Feng Zhang, MS | Amgen Inc., Thousand Oaks, CA | Author        | Analyzed the data, interpreted the data, drafted the manuscript for intellectual content |
| Sunfa Cheng, MD | Amgen Inc., Thousand Oaks, CA | Author        | Interpreted the data, drafted the manuscript for intellectual content, revised the manuscript for intellectual content |
| Hernan Picard, MD, PhD | Amgen Inc., Thousand Oaks, CA | Author        | Interpreted the data, drafted the manuscript for intellectual content, revised the manuscript for intellectual content |
| Osa Eisele, MD, MPH | Amgen Inc., Thousand Oaks, CA | Author        | Interpreted the data, drafted the manuscript for intellectual content, revised the manuscript for intellectual content |

Appendix (continued)

| Name            | Location                              | Role          | Contribution                                                                 |
|-----------------|---------------------------------------|---------------|-----------------------------------------------------------------------------|
| Julie Wang, DPM | Amgen Inc., Thousand Oaks, CA | Author        | Drafted the manuscript for intellectual content, revised the manuscript for intellectual content |
| Jonathan N. Latham, PharmD | PharmaScribe, LLC, Atlanta, GA | Author        | Drafted the manuscript for intellectual content, revised the manuscript for intellectual content |
| Daniel D. Mikol, MD, PhD | Amgen Inc., Thousand Oaks, CA | Author        | Analyzed the data, interpreted the data, drafted the manuscript for intellectual content, revised the manuscript for intellectual content |

References

1. GBD 2016 Headache Collaborators. Global, regional, and national burden of migraine and tension-type headache, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 2018;17:954–976.
2. US Burden of Disease Collaborators, Mokdad AH, Ballestrero K, et al. The state of US health, 1990-2016: burden of diseases, injuries, and risk factors among US States. JAMA 2018;319:1444–1472.
3. Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML, Stewart WF. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology 2007;68: 343–349.
4. Diamond S, Bigal ME, Silberstein S, Loder E, Reed M, Lipton RB. Patterns of diagnosis and acute and preventive treatment for migraine in the United States: results from the American Migraine Prevalence and Prevention Study. Headache 2007;47: 355–363.
5. Blumenfeld AM, Bloudek LM, Becker WJ, et al. Patterns of use and reasons for discontinuation of prophylactic medications for episodic migraine and chronic migraine: results from the second International Burden of Migraine Study (IBMS-II). Headache 2013;53:644–655.
6. Hepp Z, Dodick DW, Varon SF, Gáldar P, Hansen RN, Devine EB. Adherence to oral migraine-preventive medications among patients with chronic migraine. Cephalalgia 2015;35:478–488.
7. Ho TW, Edvinsson L, Goadsby PJ. CGRP and its receptors provide new insights into migraine pathophysiology. Nat Rev Neurol 2010;6:573–582.
8. Edvinsson L, Haanes KA, Warwinge K, Krause DN. CGRP as the target of new migraine therapies-successful transition from bench to clinic. Nat Rev Neurol 2018;14:338–350.
9. Russell FA, King R, Smillie SJ, Kojdi X, Brain SD. Calcitonin gene-related peptide: physiology and pathophysiology. Physiol Rev 2014;94:1099–1142.
10. MaassenVanDenBrink A, Tverdink GM, van den Maagdenberg AMJM. Calcitonin gene-related peptide receptor: a new target for the prevention of migraine. Genome Med 2015;7:1–10.
11. Kaur T, Winters AC, Elaisah AH, et al. Migraine and risk of cardiovascular disease in women: prospective cohort study. BMJ 2016;353:i2610.
12. Murinova N, Krashin DL, Lucas S. Vascular risk in migraineurs: interaction of endothelial and cortical excitability factors. Headache 2014;54:583–590.
13. Mahmud AN, Mentar A, Elgendy AY, et al. Migraine and the risk of cardiovascular and cerebrovascular events: a meta-analysis of 16 cohort studies including 1 152 407 subjects. BMJ Open 2018;8:e020498.
14. Wackenfors A, Jarvisius M, Ingemansson R, Edvinsson L, Malmsjö M. Triptans induce vasoconstriction of human arteries and veins from the thoracic wall. J Cardiovasc Pharmacol 2005;45:476–484.
15. Silberstein SD. The pharmacology of ergotamine and dihydroergotamine. Headache 1997;37(suppl 1):S15–S25.
16. Shi L, Lehto SG, Zhu DX, et al. Pharmacologic characterization of AMG 334, a potent and selective human monoclonal antibody against the calcitonin gene-related peptide receptor. J Pharmacol Exp Ther 2016;356:223–231.
17. Tepper S, Ashina M, Reuter U, et al. Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol 2017;16:425–434.
18. Goadsby PJ, Reuter U, Hallström Y, et al. A controlled trial of erenumab for episodic migraine. N Engl J Med 2017;377:2123–2132.
19. Sun H, Dodick DW, Silberstein S, et al. Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Neurol 2016;15:382–390.
20. Dodick DW, Ashina M, Brandes JL, et al. ARISE: a phase 3 randomized trial of erenumab for episodic migraine. Cephalalgia 2018;38:1026–1037.
21. Ashina M, Dodick D, Goadsby PJ, et al. Erenumab (AMG 334) in episodic migraine: interim analysis of an ongoing open-label study. Neurology 2017;89:1237–1243.
22. de Hoon J, Van Hecken A, Vandermeulen C, et al. Phase I, randomized, double-blind, placebo-controlled, single-dose, and multiple-dose studies of erenumab in healthy subjects and patients with migraine. Clin Pharmacol Ther 2018;103:815–825.
23. Corrado D, Link MS, Calkins H. Arrhythmogenic right ventricular cardiomyopathy. N Engl J Med 2017;376:61–72.
24. Lipton RB, Reed ML, Kurth T, Fanning KM, Buse DC. Framingham-based cardiovascular risk estimates among people with episodic migraine in the US population: results from the American Migraine Prevalence and Prevention (AMPP) study. Headache 2017;57:1507–1521.
25. Ohlsson L, Haanes K, Kronvall E, Xu C, Snellman J, Edvinsson L. Erenumab (AMG 334), a monoclonal antagonist antibody against the canonical CGRP receptor, does not impair vasodilatory or contractile responses to other vasoactive agents in human isolated cranial arteries. Epub 2019 Jul 31.
26. Beltrán AER, Ramírez AL, Bogers AJ, et al. Pharmacological selectivity of inhibition of CGRP-induced relaxations by erenumab-studied in human isolated internal mammary artery (abstract MTIS2018-041). Cephalalgia 2018;38:30.
27. Poyner D. Pharmacology of receptors for calcitonin gene-related peptide and amylin. Trends Pharmacol Sci 1995;16:424–428.
28. Walker CS, Hay DL. CGRP in the trigeminovascular system: a role for CGRP, adrenomedullin and amylin receptors? Br J Pharmacol 2013;170:1293–1307.
29. Walker CS, Efekhan S, Bower RL, et al. A second trigeminal CGRP receptor: function and expression of the AMY1 receptor. Ann Clin Transl Neurol 2015;2:595–608.
30. Depre C, Antalik L, Starling A, et al. A randomized, double-blind, placebo-controlled study to evaluate the effect of erenumab on exercise time during a treadmill test in patients with stable angina. Headache 2018;58:715–723.
Vascular safety of erenumab for migraine prevention
David Kudrow, Julio Pascual, Paul K. Winner, et al.
Neurology 2020;94:e497-e510 Published Online before print December 18, 2019
DOI 10.1212/WNL.0000000000008743

This information is current as of December 18, 2019

Updated Information & Services
including high resolution figures, can be found at:
http://n.neurology.org/content/94/5/e497.full

References
This article cites 29 articles, 5 of which you can access for free at:
http://n.neurology.org/content/94/5/e497.full#ref-list-1

Citations
This article has been cited by 1 HighWire-hosted articles:
http://n.neurology.org/content/94/5/e497.full##otherarticles

Subspecialty Collections
This article, along with others on similar topics, appears in the following collection(s):
Migraine
http://n.neurology.org/cgi/collection/migraine
Patient safety
http://n.neurology.org/cgi/collection/patient__safety

Errata
An erratum has been published regarding this article. Please see next page or:
/content/94/23/1052.2.full.pdf

Permissions & Licensing
Information about reproducing this article in parts (figures,tables) or in its entirety can be found online at:
http://www.neurology.org/about/about_the_journal#permissions

Reprints
Information about ordering reprints can be found online:
http://n.neurology.org/subscribers/advertise

Neurology © is the official journal of the American Academy of Neurology. Published continuously since 1951, it is now a weekly with 48 issues per year. Copyright Copyright © 2019 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.. All rights reserved. Print ISSN: 0028-3878. Online ISSN: 1526-632X.
Disputes & Debates: Editors’ Choice

Steven Galetta, MD, FAAN, Section Editor

Editors’ note: Epidemiology of NMOSD in Sweden from 1987 to 2013: A nationwide population-based study

In their retrospective observational cohort study of 294 patients with neuromyelitis optica spectrum disorder (NMOSD), Drs. Jonsson et al. summarized the rising incidence rate of this condition in Sweden between 1987 and 2013. The investigators postulate that the higher incidence rate—0.79 per 1,000,000 person-years from 0.30 per 1,000,000 person-years—may have been attributed, in part, to heightened awareness of the disease and greater availability of MRI and NMO antibody testing. These incidence estimates mirror what have been reported in other predominantly Caucasian cohorts. In response, Drs. Papp et al. reiterate that although incidence and prevalence estimates are similar between nations of similar ethnic profiles, Southern Denmark has reported some of the highest prevalence (4.4 per 100,000 person-years) and incidence rates (4.0 per 1,000,000 person-years). Drs. Jonsson et al. comment that the higher estimates reported by Asgari et al. from Southern Denmark may be partially explained by the prospective nature of their study and the fact that patients from that study were evaluated for NMOSD even if optic neuritis was the presenting symptom. Based on the collective results from these studies, it is likely that NMOSD remains an underrecognized condition, and physicians should have a lower threshold to evaluate these patients with serum antibody testing and MRI, given the treatment considerations that are specific to NMOSD compared with MS. A correction to figure 5 was published in the September 10, 2019, issue of Neurology.

James E. Siegler III, MD, and Steven Galetta, MD
Neurology® 2020;94:1048. doi:10.1212/WNL.0000000000009598

Reader response: Epidemiology of NMOSD in Sweden from 1987 to 2013: A nationwide population-based study

Viktoria Papp (Odense, Denmark), Thor Petersen (Aarhus, Denmark), Melinda Magyari (Copenhagen), Nils Koch-Henriksen (Aarhus, Denmark), Jette Lautrup Frederiksen (Glostrup, Denmark), Finn Sellebjerg (Copenhagen), Egon Stenager (Odense, Denmark), and Zsolt Illes (Odense, Denmark)
Neurology® 2020;94:1048–1049. doi:10.1212/WNL.0000000000009602

We read the nationwide Swedish epidemiologic study of neuromyelitis optica spectrum disorder (NMOSD) published by Jonsson et al. with great interest. The study revealed similar prevalence (1.04 per 100,000 people [CI: 0.85–1.26]) and incidence (0.79 per 1,000,000 person-years [CI: 0.55–1.03]) of NMOSD to the prevalence (1.09 per 100,000 people [CI: 0.81–1.44]) and incidence (0.70 per 1,000,000 person-years [CI: 0.46–1.02]) estimates of the recent nationwide Danish study and also to the incidence study of NMOSD from the Region of Central Denmark (incidence: 0.12 per 1,000,000 person-years). These studies from Scandinavia showed similar data to each other and also to other white populations, and they contrast with the results of the study from the region of Southern Denmark, reporting the highest prevalence (4.4 per 100,000 people [CI: 3.1–5.7]) and incidence (4.0 per 1,000,000 person-years [CI: 3.0–5.4]) so far in a predominantly Caucasian population.
We would also like to bring attention to figure 5 (Comparison of incidence and prevalence in Sweden with other regions) concerning the incidence estimates. The incidence of NMOSD in Australia and New Zealand published by Bukhari et al. is 0.37 per 1,000,000 person-years (CI: 0.35–0.39) and not 3.7 per 1,000,000 person-years (CI: 3.5–3.9), as it is incorrectly shown in figure 5.

1. Jonsson DI, Sveinsson O, Hakim R, et al. Epidemiology of NMOSD in Sweden from 1987 to 2013: a nationwide population-based study. Neurology 2019;93:e181–e189.
2. Papp V, Illés Z, Magaszi M, et al. Nationwide prevalence and incidence study of neuromyelitis optica spectrum disorder in Denmark. Neurology 2018;91:e2265–e2275.
3. Dale GH, Svendsen KB, Gjolstrup MC, et al. Incidence of neuromyelitis optica spectrum disorder in the Central Denmark Region. Acta Neurol Scand 2018;137:582–588.
4. Asgari N, Løvelund ST, Skejoe HP, et al. A population-based study of neuromyelitis optica in Caucasians. Neurology 2011;76:1589–1595.
5. Bukhari W, Prain KM, Waters P, et al. Incidence and prevalence of NMOSD in Australia and New Zealand. J Neurol Neurosurg Psychiatry 2017;88:632–638.

Author response: Epidemiology of NMOSD in Sweden from 1987 to 2013: A nationwide population-based study

Dagur I. Jonsson (Stockholm), Olafur Sveinsson (Stockholm), Ramil Hakim (Stockholm), and Lou Brundin (Stockholm)

Neurology® 2020;94:1049–1050. doi:10.1212/WNL.0000000000009601

We are grateful for the comments on our article1 from our Danish colleagues who recently conducted a similar study2 applying comparable methods. These studies were conducted in parallel, and independent from each other, in ethnically similar populations, strengthening the results of both studies. The study by Asgari3 in 2011 was conducted differently, and data were collected prospectively and involved ophthalmology departments in the Southern Denmark region. Importantly, the study by Asgari implied that there may be an undetected population of patients with neuromyelitis optica spectrum disorder (NMOSD) with optic neuritis as an onset symptom, which is missed. This could partly account for the differing results. Also, Papp et al. correctly pointed out that in figure 5 of our article,1 we mistakenly reported the incidence of NMOSD in Australia and New Zealand4 as 3.7 per 1,000,000 person-years (CI: 3.5–3.9). The correct incidence is 0.37 per 1,000,000 person-years (CI: 0.35–0.39). We are sorry for the mistake and thankful for the correction. The corrected figure does not in any way change the conclusions put forward in our article.
Incidence (A) and prevalence (B) of neuromyelitis optica/neuromyelitis optica spectrum disorder in other regions from available publications. Horizontal error bars represent the mean surrounded by a 95% CI.

1. Jonsson DI, Sveinsson O, Hakim R, Brandin L. Epidemiology of NMOSD in Sweden from 1987 to 2013: a nationwide population-based study. Neurology 2019;93:e181–e189.
2. Papp V, Illes Z, Magyari M, et al. Nationwide prevalence and incidence study of neuromyelitis optica spectrum disorder in Denmark. Neurology 2018;91:e2265–e2275.
3. Asgari N, Lillevang ST, Skejoe HP, et al. A population-based study of neuromyelitis optica in Caucasians. Neurology 2011;76:1589–1595.
4. Bukhari W, Prain KM, Waters P, et al. Incidence and prevalence of NMOSD in Australia and New Zealand. J Neurol Neurosurg Psychiatry 2017;88:632–638.

Copyright © 2020 American Academy of Neurology

Author disclosures are available upon request (journal@neurology.org).
Editors’ note: Low hemoglobin and hematoma expansion after intracerebral hemorrhage

To corroborate previous reports that lower hemoglobin levels may be associated with hematoma expansion (HE) and poor functional outcomes after intracerebral hemorrhage (ICH), Drs. Roh et al. queried their single-center prospective ICH registry of 256 patients. After adjustment for known predictors of HE, each 1 g/dL fall in hemoglobin levels was associated with a 20% higher odds of HE and 24% higher odds of severe disability (modified Rankin Scale score 4–6) at 3 months. Mediation analysis demonstrated that HE contributed to the poor long-term outcomes seen in patients with lower admission hemoglobin levels. Yu et al. address important unmeasured confounders—notably, coagulopathy—which could have also contributed to adverse radiographic and clinical outcomes. However, as Dr. Roh responds, patients in this study were excluded if there was evidence of coagulopathy secondary to systemic disease. Furthermore, the investigators adjusted for the use of therapeutic anticoagulation, irrespective of coagulation studies. Ultimately, both groups agree that these results warrant replication in further studies.

James E. Siegler III, MD, and Steven Galetta, MD

Neurology® 2020;94:1051. doi:10.1212/WNL.0000000000009604

Reader response: Low hemoglobin and hematoma expansion after intracerebral hemorrhage

Zhiyuan Yu (Chengdu, China), Jun Zheng (Chengdu, China), and Chao You (Chengdu, China)

Neurology® 2020;94:1051. doi:10.1212/WNL.0000000000009607

With interest and appreciation, I read the article by Roh et al.,1 which suggested that low hemoglobin levels could be related to hematoma expansion in intracerebral hemorrhage. Although previous studies have shown anemia is associated with worse outcomes in these patients,2,3 the study by Roh et al. is the first one showing that hematoma expansion mediates this association. However, some issues should be noted.

The time from onset to baseline CT was relatively long (median 5.6 hours), which could influence the identification of hematoma expansion. Moreover, some important results of laboratory coagulation testing, such as prothrombin time and international normalized ratio, were not included in multivariate logistic regression, which could make the results not robust enough. Therefore, their findings still need to be confirmed by further studies.

1. Roh DJ, Albers DJ, Magid-Bernstein J, et al. Low hemoglobin and hematoma expansion after intracerebral hemorrhage. Neurology 2019;93:e372–e380.
2. Kuramatsu JB, Gerner ST, Lücking H, et al. Anemia is an independent prognostic factor in intracerebral hemorrhage: an observational cohort study. Crit Care 2013;17:R148.
3. Zhang S, Pan X, Wei C, et al. Associations of anemia with outcomes in patients with spontaneous intracerebral hemorrhage: a meta-analysis. Front Neurol 2019;10:406.

Copyright © 2020 American Academy of Neurology
The comments posited by Yu et al.\(^1\) appropriately highlight limitations of single-center observational data and the importance of external replication for our findings. While adjusting for laboratory coagulation testing is important to consider, it is worth noting that we excluded patients with laboratory evidence of coagulopathy because of systemic medical disease. In addition, we adjusted for anticoagulation use, which should account for prothrombin time/international normalized ratio elevations due to a medication effect. Subsequently, it would be unlikely that the addition of laboratory coagulation markers in a multivariable model would affect the conclusions seen in our cohort.

If our findings are replicated, the need to study the mechanism(s) behind the findings is important. Given that underlying medical illness can be associated with lower hemoglobin levels, it is plausible that the relationship of lower hemoglobin levels with hematoma expansion and poor outcomes seen in our cohort is driven by the underlying disease rather than the hemoglobin level itself. Translational studies may be the only way to disentangle this potentially confounding factor; it is important to consider this factor before advocating for liberal red blood cell transfusion in intracerebral hemorrhage, as there are known complications associated with unnecessary red blood cell transfusions.

1. Roh DJ, Albers DJ, Magid-Bernstein J, et al. Low hemoglobin and hematoma expansion after intracerebral hemorrhage. Neurology 2019;93:e372–e380.

CORRECTION

Vascular safety of erenumab for migraine prevention

In the article "Vascular safety of erenumab for migraine prevention" by Kudrow et al.,\(^1\) Dr. Pascual’s affiliation should have been listed as the University of Cantabria. The authors regret the error.

Reference

1. Kudrow D, Pascual J, Winner PK, et al. Vascular safety of erenumab for migraine prevention. Neurology 2020;94:e497–e510.